

Memphasys Extends Convertible Note Repayment Terms with Long-Term Shareholder Peters Investments

Memphasys Limited (ASX: MEM) advises that it has executed an amendment deed with Peters Investments Pty Ltd, a major long-term shareholder, to extend the repayment terms of its existing convertible note agreements.

Under the amendment, the maturity date of the convertible notes has been extended to 30 June 2026, providing the Company with additional time and flexibility in managing its repayment obligations. A structured timetable for the cash repayment of accrued interest has also been agreed. The amendments do not alter the principal amount outstanding under the notes, nor does it change the existing conversion terms.

The Board considers the extension of the repayment terms to be a key component of the Company's focused execution strategy, strengthening balance sheet flexibility while Memphasys continues to progress its commercial and regulatory objectives. Peters Investments has been a shareholder of the Company for many years, and the Board views this amendment as a strong signal of the continued confidence in both the Company and the strategic direction being implemented by the current Board.

All other terms and conditions of the convertible note agreements remain unchanged.

Lindley Edwards Chairperson of Memphasys Limited, said:

"The extension of the repayment terms provides Memphasys with greater flexibility as we continue to execute on our commercial and regulatory priorities. Peters Investments has been a long-standing shareholder, and their ongoing support reflects alignment with the strategy the Board is delivering."

Mr Robert (Bob) Peters, Director of Peters Investments Pty Ltd, commented:

"We remain supportive of Memphasys and confident in the direction being taken by the current Board. Extending the repayment terms reflects our long-term commitment to the Company as it continues to execute its strategy."

The amendment follows a period of strong operational progress for Memphasys, including CE Mark approval¹ and the execution of commercial agreements with Centro Fertilità Assistita (CFA)² Italia, International Technical Legacy³, and the Andrology Center Coimbatore⁴ group in India, together with the receipt of early commercial orders.

¹ ASX announcement dated 29 December 2025

² ASX announcement dated 22 December 2025

³ ASX announcements dated 18 December 2025, 8 & 18 September 2025

⁴ ASX announcement dated 28 October 2025

The Board considers 2026 to represent a continuation of the step-change in strategic and operational execution initiated in 2025, positioning Memphasys to build on recent achievements and progress toward sustained commercialisation.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.